慢性肝病患者接种新型冠状病毒冠疫苗研究进展
Research Progress of Novel Coronavirus Vac-cine in Patients with Chronic Liver Disease
DOI: 10.12677/ACM.2023.134943, PDF,   
作者: 王 露, 石小枫*：重庆医科大学附属第二医院感染科，重庆
关键词: 新型冠状病毒冠疫苗；慢性肝病；肝硬化；SARS-CoV-2 Vaccine； Liver Diseases； Cirrhosis
摘要: 慢性肝病患者发生严重新型冠状病毒疾病的风险和相关死亡率高于普通人群。欧洲肝病协会及美国肝病协会建议慢性肝病患者优先接种新型冠状病毒冠疫苗(以下简称新冠疫苗)，然而，考虑到这些患者临床试验数据较少，疫苗的有效性以及疫苗相关不良事件的风险仍存在不确定性。在本综述中，我们总结了自新冠疫苗问世以来在慢性肝病患者中开展研究的相关结果。
Abstract: Patients with chronic liver disease have a higher risk of severe novel coronavirus disease and asso-ciated mortality than the general population. The European Hepatology Association and the Ameri-can Hepatology Association recommend that patients with chronic liver disease be given priority for the novel coronavirus vaccine (COVID-19 vaccine). However, given the limited clinical trial data for these patients, there is still uncertainty about the effectiveness of the vaccine and the risk of vac-cine-related adverse events. In this review, we summarize the results of studies conducted in pa-tients with chronic liver disease since the introduction of COVID-19 vaccines.
文章引用：王露, 石小枫. 慢性肝病患者接种新型冠状病毒冠疫苗研究进展[J]. 临床医学进展, 2023, 13(4): 6745-6749. https://doi.org/10.12677/ACM.2023.134943

参考文献

[1] Wang, Y., Liu, S., Liu, H., et al. (2020) SARS-CoV-2 Infection of the Liver Directly Contributes to Hepatic Impairment in Patients with COVID-19. Journal of Hepatology, 73, 807-816. [Google Scholar] [CrossRef] [PubMed]
[2] Lagana, S.M., Kudose, S., Iuga, A.C., et al. (2020) Hepatic Pa-thology in Patients Dying of COVID-19: A Series of 40 Cases including Clinical, Histologic, and Virologic Data. Mod-ern Pathology, 33, 2147-2155. [Google Scholar] [CrossRef] [PubMed]
[3] Sonzogni, A., Previtali, G., Seghezzi, M., et al. (2020) Liver Histopathology in Severe COVID 19 Respiratory Failure Is Suggestive of Vascular Alterations. Liver International, 40, 2110-2116. [Google Scholar] [CrossRef] [PubMed]
[4] Marjot, T., Moon, A.M., Cook, J.A., et al. (2021) Outcomes Following SARS-CoV-2 Infection in Patients with Chronic Liver Disease: An International Registry Study. Journal of Hepatology, 74, 567-577. [Google Scholar] [CrossRef] [PubMed]
[5] Ekpanyapong, S., Bunchorntavakul, C. and Reddy, K.R. (2022) COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, a Year Later. Journal of Viral Hepatitis, 29, 4-20. [Google Scholar] [CrossRef] [PubMed]
[6] Cornberg, M., Buti, M., Eberhardt, C.S., et al. (2021) EASL Position Paper on the Use of COVID-19 Vaccines in Patients with Chronic Liver Diseases, Hepatobiliary Cancer and Liver Transplant Recipients. Journal of Hepatology, 74, 944-951. [Google Scholar] [CrossRef] [PubMed]
[7] Fix, O.K., Blumberg, E.A., Chang, K.M., et al. (2021) American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients with Liver Disease. Hepatol-ogy, 74, 1049-1064. [Google Scholar] [CrossRef] [PubMed]
[8] He, T., Zhou, Y., Xu, P., et al. (2022) Safety and An-tibody Response to Inactivated COVID-19 Vaccine in Patients with Chronic Hepatitis B Virus Infection. Liver Interna-tional, 42, 1287-1296. [Google Scholar] [CrossRef] [PubMed]
[9] Xiang, T., Liang, B., Wang, H., et al. (2021) Safety and Immunogenicity of a SARS-CoV-2 Inactivated Vaccine in Patients with Chronic Hepatitis B Virus Infection. Cellu-lar & Molecular Immunology, 18, 2679-2681. [Google Scholar] [CrossRef] [PubMed]
[10] 刘星, 吴威, 张晓明, 等. 非酒精性脂肪性肝病及原发性肝细胞癌患者接种新型冠状病毒灭活疫苗的安全性及免疫原性[J]. 新发传染病电子杂志, 2022, 7(3): 50.
[11] Wang, J., Hou, Z., Liu, J., et al. (2021) Safety and Immunogenicity of COVID-19 Vaccination in Patients with Non- Alcoholic Fatty Liver Disease (CHESS2101): A Multicenter Study. Journal of Hepatology, 75, 439-441. [Google Scholar] [CrossRef] [PubMed]
[12] Cheung, K.S., Lam L.K., Hui, R.W.H., et al. (2022) Effect of Moderate-to-Severe Hepatic Steatosis on Neutralising Antibody Response among BNT162b2 and CoronaVac Recipients. Clinical and Molecular Hepatology, 28, 553. [Google Scholar] [CrossRef] [PubMed]
[13] Kearns, P., Siebert, S., Gaskell, C., et al. (2021) Examining the Im-munological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity—The OCTAVE Trial. [Google Scholar] [CrossRef] 
[14] Duengelhoef, P., Hartl, J., Rüther, D., et al. (2022) SARS-CoV-2 Vac-cination Response in Patients with Autoimmune Hepatitis and Autoimmune Cholestatic Liver Disease. United European Gastroenterology Journal, 10, 319-329. [Google Scholar] [CrossRef] [PubMed]
[15] Schneider, L., Schubert, L., Winkler, F., et al. (2022) SARS-CoV-2 Vac-cine Response in Patients with Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 20, 2145-2147.e2. [Google Scholar] [CrossRef] [PubMed]
[16] Efe, C., Taşçılar, K., Gerussi, A., et al. (2022) SARS-CoV-2 Vac-cination and Risk of Severe COVID-19 Outcomes in Patients with Autoimmune Hepatitis. Journal of Autoimmunity, 132, Article ID: 102906. [Google Scholar] [CrossRef] [PubMed]
[17] Garrido, I., Lopes, S., Simões, M.S., et al. (2021) Autoimmune Hepatitis after COVID-19 Vaccine—More than a Coincidence. Journal of Autoimmunity, 125, Article ID: 102741. [Google Scholar] [CrossRef] [PubMed]
[18] Bril, F., Al Diffalha, S., Dean, M., et al. (2021) Autoimmune Hep-atitis Developing after Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty? Journal of Hepatology, 75, 222-224. [Google Scholar] [CrossRef] [PubMed]
[19] McShane, C., Kiat, C., Rigby, J., et al. (2021) The mRNA COVID-19 Vaccine—A Rare Trigger of Autoimmune Hepatitis? Journal of Hepatology, 75, 1252-1254. [Google Scholar] [CrossRef] [PubMed]
[20] Avci, E. and Abasiyanik, F. (2021) Autoimmune Hepatitis after SARS-CoV-2 Vaccine: New-Onset or Flare-Up? Journal of Autoimmunity, 125, Article ID: 102745. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, Y., Xu, Z., Wang, P., et al. (2022) New-Onset Autoimmune Phenomena Post-COVID-19 Vaccination. Immunology, 165, 386-401. [Google Scholar] [CrossRef] [PubMed]
[22] Perumalswami, P., Peng, L. and Odin, J.A. (2009) Vaccination as a Trig-gering Event for Autoimmune Hepatitis. Seminars in Liver Disease, 29, 331-334. [Google Scholar] [CrossRef] [PubMed]
[23] Sasaki, T., Suzuki, Y., Ishida, K., et al. (2018) Autoimmune Hepatitis Following Influenza Virus Vaccination: Two Case Reports. Medicine, 97, e11621. [Google Scholar] [CrossRef] 
[24] Lleo, A., Cazzagon, N., Rigamonti, C., et al. (2022) Clinical Update on Risks and Efficacy of Anti-SARS-CoV-2 Vaccines in Patients with Autoimmune Hepatitis and Summary of Reports on Post-Vaccination Liver Injury. Digestive and Liver Disease, 54, 722-726. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, J., Zhang, Q., Ai, J., et al. (2022) Safety and Immunogenicity of SARS-CoV-2 Vaccines in Chinese Patients with Cirrhosis: A Prospective Multicenter Study. Hepatology Internation-al, 16, 691-701. [Google Scholar] [CrossRef] [PubMed]
[26] Cheung, K.S., Mok, C.H., Mao, X., et al. (2022) COVID-19 Vaccine Immunogenicity among Chronic Liver Disease Patients and Liver Transplant Recipients: A Meta-Analysis. Clinical and Molecular Hepatology, 28, 890-911. [Google Scholar] [CrossRef] [PubMed]
[27] Gupta, R.K. (2021) Will SARS-CoV-2 Variants of Concern Affect the Promise of Vaccines? Nature Reviews Immunology, 21, 340-341. [Google Scholar] [CrossRef] [PubMed]
[28] Efe, C., Lammert, C., Taşçılar, K., et al. (2022) Effects of Im-munosuppressive Drugs on COVID-19 Severity in Patients with Autoimmune Hepatitis. Liver International, 42, 607-614. [Google Scholar] [CrossRef] [PubMed]

为你推荐